3801-89-6

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-Fluorophenyl)piperazine is used as an active pharmaceutical ingredient for the development of medications targeting various medical conditions. Its specific application reason is due to its structural properties that may allow it to interact with specific biological targets or receptors in the body.
Used in Veterinary Medicine:
1-(3-Fluorophenyl)piperazine is used as an anthelmintic agent for the treatment of parasitic worms in animals. Its application reason is based on its ability to effectively target and eliminate parasites, improving the health and well-being of the animals being treated.

InChI:InChI=1/C10H13FN2/c11-9-2-1-3-10(8-9)13-6-4-12-5-7-13/h1-3,8,12H,4-7H2

Upstream product

• 1073-06-9 3-fluorobromobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 110-85-0 piperazine 
• 625-98-9 3-chlorofluorobenzene 
• 951626-85-0 tert-butyl 4-(3-fluorophenyl)piperazine-1-carboxylate 
• 372-19-0 meta-fluoroaniline 
• 821-48-7 bis-(2-chloroethyl)amine hydrochloride 

Downstream Products

• 72222-97-0 3-[4-(3-fluoro-phenyl)-piperazin-1-yl]-2H-benzo[1,4]oxazine 
• 57962-06-8 2-{2-[4-(3-fluoro-phenyl)-piperazin-1-yl]-ethyl}-quinoline 
• 78069-82-6 1-(3-Fluoro-phenyl)-4-(3-nitro-pyridin-4-yl)-piperazine 
• 475652-85-8 3-[4-(3-fluoro-phenyl)-piperazin-1-yl]-1-(5-methyl-1-pyrimidin-2-yl-1H-pyrazol-4-yl)-propan-1-one 
• 946522-86-7 benzyl ester of {2-[4-(3-fluorophenyl)piperazin-1-yl]-2-oxoethyl}carbamic acid 
• 78069-83-7 4-[4-(3-Fluoro-phenyl)-piperazin-1-yl]-pyridin-3-ylamine 
• 223525-72-2 1-[4-(3-fluorophenyl)piperazin-1-yl]-3-[2-oxopyrrolidin-1-yl]propane 

Relevant academic research and scientific papers

Discovery and optimization of heteroaryl piperazines as potent and selective PI3Kδ inhibitors

A high-throughput screening (HTS) campaign identified a class of heteroaryl piperazines with excellent baseline affinity and selectivity for phosphoinositide 3-kinase δ (PI3Kδ) over closely related isoforms. Rapid evaluation and optimization of structure-activity relationships (SAR) for this class, leveraging the modular nature of this scaffold, facilitated development of this hit class into a series of potent and selective inhibitors of PI3Kδ. This effort culminated in the identification of 29, which displayed excellent potency in enzyme and cell-based assays, as well as favorable pharmacokinetic and off-target profiles.

MONOACYLGLYCEROL LIPASE INHIBITORS

Provided are compounds of formula (I), or a pharmaceutically acceptable salt or solvate thereof: Also provided are compositions comprising compounds of formula (I). The compounds and compositions are also provided for use as medicaments, for example as medicaments useful in the treatment of a condition modulated by monoacylglycerol lipase (MAGL). Also provided are the use of compounds and compositions for the inhibition of monoacylglycerol lipase (MAGL).

Evaluation of substituted n-phenylpiperazine analogs as D3 vs. D2 dopamine receptor subtype selective ligands

N-phenylpiperazine analogs can bind selectively to the D3 versus the D2 dopamine receptor subtype despite the fact that these two D2-like dopamine receptor subtypes exhibit substantial amino acid sequence homology. The binding for a number of these receptor subtype selective compounds was found to be consistent with their ability to bind at the D3 dopamine receptor subtype in a bitopic manner. In this study, a series of the 3-thiophenephenyl and 4-thiazolylphenyl fluoride substituted N-phenylpiperazine analogs were evaluated. Compound 6a was found to bind at the human D3 receptor with nanomolar affinity with substantial D3 vs. D2 binding selectivity (approximately 500-fold). Compound 6a was also tested for activity in two in-vivo assays: (1) a hallucinogenic-dependent head twitch response inhibition assay using DBA/2J mice and (2) an L-dopa-dependent abnormal involuntary movement (AIM) inhibition assay using unilateral 6-hydroxydopamine lesioned (hemiparkinsonian) rats. Compound 6a was found to be active in both assays. This compound could lead to a better understanding of how a bitopic D3 dopamine receptor selective ligand might lead to the development of pharmacotherapeutics for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease.

PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA

Provided herein is compounds of formulas (Ia) and (Ib) which are PI3K-delta inhibitors, and uses for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

Identification of novel GLUT inhibitors

The compound class of 1H-pyrazolo[3,4-d]pyrimidines was identified using HTS as very potent inhibitors of facilitated glucose transporter 1 (GLUT1). Extensive structure–activity relationship studies (SAR) of each ring system of the molecular framework was established revealing essential structural motives (i.e., ortho-methoxy substituted benzene, piperazine and pyrimidine). The selectivity against GLUT2 was excellent and initial in vitro and in vivo pharmacokinetic (PK) studies are encouraging.

Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient

The present invention is a piperazinylalkylbenzofuran derivative of the formula wherein R1 represents a C1-4 alkyl group, R2 stands for a hydrogen atom, X means an oxygen atom, Y is a hydroxyl group, Z represents a hydrogen atom, Ar′ represents a diphenylmethyl group, a pyridyl group, a partially saturated 5-membered heterocyclic group or a phenyl group, n has a value of 0 or 1, and pharmaceutically suitable acid addition salts thereof.

SUBSTITUTED DIHYDROCHINAZOLINES HAVING ANTIVIRAL PROPERTIES

The invention relates to substituted dihydrochinazolines of formula (I), methods for the production thereof, and the use thereof for producing medicaments used for treating and/or preventing diseases, particularly as antiviral agents, especially against cytomegaloviruses.

Use of 2-Oxazolidinones As Latent Aziridine Equivalents. III. Preparation of N-Substituted Piperazines.

A number of N-aryl and N-alkyl substituted piperazines 1 were prepared from variously substituted 2-oxazolidinone derivatives 3.The method involved treatment of 3 with HBr in glacial acetic acid followed by heating the resulting ring-opened salts 5 in alcoholic solvent.The piperazines 1a-1q were isolated by crystallization in yields ranging from 23-91percent.

Antiviral agents

Antiviral compounds (I): the symbols being as defined in the specification, are efficacious against infections caused by a variety of DNA viruses, RNA viruses and retroviruses. Other specified compounds also exhibit activity. The compounds have a wider spectrum of activity than known antiviral substances.

Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy

Generally, antipsychotic agents are dopamine receptor blocking agents that also block conditioned avoidance responding (CAR) in the rat. Recently, however, both (o-methoxyphenyl)piperazine (OMPP, 1h) and (m-chlorophenyl)piperazine (MCPP, 1o) have been reported to block conditioned avoidance responding in the rat although neither has dopamine receptor blocking properties. The present paper examines the behavioral and biochemical profile of a number of additional substituted phenylpiperazines. None of the phenylpiperazines tested demonstrated high affinity for either dopamine D-1 or D-2 receptor sites, yet many effective in blocking CAR. The results suggest that the phenylpiperazines may be effective antipsychotic agents without blocking dopamine receptors. Moreover, the active compounds did demonstrate activity in displacing ligand binding to serotonin receptors. Receptor binding profiles were determined for 5-HT-1A and 5-HT-1B binding sites as well as for 5-HT-2 sites. The data from this preclinical test suggest these phenylpiperazines might be effective antipsychotic agents acting via a nondopaminergic mechanism of action.